CPG
DMAC icon

Cornerstone Planning Group’s DiaMedica Therapeutics DMAC Stock Holding History

Cornerstone Planning Group’s Portfolio DMAC Stock Details DMAC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$500 Hold
80
– – ﹤0.01% 1648
2025
Q4 		$675 Buy
80
+74
+1,233% +$553 ﹤0.01% 1443
2025
Q3 		$758 Sell
6
-74
-93% -$401 ﹤0.01% 1378
2025
Q2 		$359 Hold
80
– – ﹤0.01% 1388
2025
Q1 		$317 Hold
80
– – ﹤0.01% 1397
2024
Q4 		$485 Hold
80
– – ﹤0.01% 1151
2024
Q3 		$346 Buy
+80
New +$295 ﹤0.01% 1165

Other funds holding DMAC

CLG
Cooperman Leon G $3.05B AUM 42.78% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
PAPAIJV
Paragon Associates & Paragon Associates II Joint Venture Dallas, Texas $73.6M AUM 61.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return
BL
Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Cornerstone Planning Group's DMAC Position: Q1 2026 in Review

Cornerstone Planning Group held its DiaMedica Therapeutics (DMAC) position steady in Q1 2026 at 80 shares worth $500. The position accounts for ﹤0.01% of the portfolio, ranked #1648.

Cornerstone Planning Group first reported a position in DMAC in Q3 2024 and has held it in 7 quarters since. The position peaked at $758 in Q3 2025. 98 funds tracked by Wall St. Rank hold DMAC as of Q1 2026.

  • Cornerstone Planning Group held 80 shares of DiaMedica Therapeutics worth $500 as of Q1 2026.
  • Cornerstone Planning Group left its DiaMedica Therapeutics share count unchanged in Q1 2026.
  • DiaMedica Therapeutics made up ﹤0.01% of Cornerstone Planning Group's portfolio in Q1 2026, its #1648 holding.
  • Cornerstone Planning Group first reported a position in DiaMedica Therapeutics in Q3 2024 and has held it in 7 quarters since.
  • Cornerstone Planning Group's DiaMedica Therapeutics position peaked at $758 in Q3 2025.
  • 98 funds tracked by Wall St. Rank held DiaMedica Therapeutics as of Q1 2026.

Based on Cornerstone Planning Group's 13F filing for Q1 2026, filed 6 May 2026.